brexpiprazole + fluoxetine

Brexpiprazole + fluoxetine is a combination of two pharmaceutical agents: brexpiprazole, a second-generation (atypical) antipsychotic, and fluoxetine, a selective serotonin reuptake inhibitor (SSRI). The combination has been studied as an adjunctive treatment in major depressive disorder, particularly for treatment-resistant cases. Preclinical studies indicate that the combination produces a rapid antidepressant effect not achieved by either drug alone, likely mediated via the brain-derived neurotrophic factor (BDNF) - TrkB signaling pathway and actions on neuronal dendritic spine density in critical brain regions including the prefrontal cortex, hippocampus, and nucleus accumbens[1][3].